CVS Health’s latest announcement comes amid growing scrutiny from regulators and lawmakers over the relationship between pharmacy benefit managers and the pharmacies they own.
At first glance, separating CVS’s retail pharmacies from its insurance and PBM operations might appear to address those concerns. But the most consequential detail is what stays together: Aetna, Caremark and CVS Specialty.
For covered entities, understanding that distinction matters more than the breakup headlines.
What did CVS announce?
On November 4, CVS Health announced plans to separate into two independent, publicly traded companies, with completion expected in the first half of 2028.
CVS Pharmacy will include approximately 9,000 retail pharmacies, mail pharmacy, MinuteClinic, including virtual care, and the Health100 technology services business. Prem Shah, currently CVS Health’s group president, will lead the company.
CVS Health, an interim name for the healthcare solutions company, will include Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health. David Joyner will lead that business.
The proposal separates retail pharmacy from the insurance and PBM businesses while preserving common ownership of insurance, pharmacy benefits and specialty dispensing. CVS says medications, care and benefits will continue uninterrupted during the transition.
Here are four things covered entities should consider.
1. Clinic-Owned pharmacy infrastructure deserves even greater attention
The planned transition introduces another variable into an already changing community pharmacy landscape. CVS has not announced additional store closures as part of this separation. However, covered entities should assess how dependent their patients and programs are on outside pharmacy partners, and what happens if those partners change their footprint, contracts or operating priorities.
For vulnerable patients, a change in pharmacy access can complicate medication delivery, communication with their care team and continuity of treatment. For covered entities, changes to contract pharmacy relationships can also affect the resources available to support patient services.
For clinics where the model is viable, investing in an entity-owned pharmacy can provide greater control over access, care coordination and program sustainability. Ownership still requires navigating payer networks and reimbursement, but it gives clinics a more direct role in managing a critical part of patient care.
The coming transition reinforces the importance of evaluating that investment.
2. Specialty network restrictions do not disappear with This announcement
Nothing in the announcement establishes broader access for unaffiliated pharmacies to specialty networks. When a patient needs an HCV medication such as Epclusa, a plan requiring CVS Specialty could still require CVS Specialty. Separating the retail stores does not, by itself, change that requirement.
This is a central distinction for covered entities that operate their own pharmacies. A clinic may have the clinical expertise, inventory and patient relationship needed to dispense a medication, yet still encounter a network restriction requiring the prescription to be filled elsewhere. Because CVS Specialty will remain alongside Caremark and Aetna, covered entities should not assume this restructuring will resolve or change those barriers in any meaningful way.
3. Vertical integration (still) remains central to the strategy
The remaining healthcare solutions company will more closely resemble the model used by UnitedHealth Group: insurance, a PBM, specialty pharmacy and care delivery under one roof.
My read is that CVS is drawing a new boundary around its businesses while retaining the integration it considers most valuable. Specialty pharmacy is particularly consequential. The FTC has documented concerns at pharmacies affiliated with the largest PBMs, as well as dispensing patterns suggesting that highly profitable prescriptions may be steered toward affiliated pharmacies.
Retaining CVS Specialty preserves the ownership relationship at the center of those concerns. The question for covered entities is therefore how this restructuring will change the incentives, network decisions and dispensing relationships that affect their patients.
4. The 340B implications remain unclear
The announcement does not provide a breakdown of CVS’s 340B contract pharmacy revenue between retail and specialty dispensing. That leaves important questions about how the separation could affect covered entities’ agreements, economics and patient access.
Which company will hold particular contract pharmacy relationships? Will existing terms continue? How will shared services and arrangements between retail and specialty pharmacy operate? Will covered entities face changes in administration or costs The announcement does not answer those questions. The eventual allocation of contracts and the commercial arrangements between the two companies will matter more than their names.
What covered entities should do now
Start with a practical assessment of your contract pharmacy relationships:
- Map your contract pharmacy dependence. Determine how much of your prescription volume and total 340B proceeds comes through contract pharmacies, with a specific focus on CVS.
- Separate CVS retail from CVS Specialty. Break out CVS dependence between retail chain locations and specialty pharmacy. For each, measure:
- Number of prescriptions and percentage of total contract pharmacy volume.
- Total 340B proceeds and percentage of total contract pharmacy proceeds.
- Identify patient access risks. Determine which patients and medications depend on CVS because of specialty network requirements, location or delivery needs. Document the alternatives available if those arrangements change.
- Review your agreements. Check renewal dates, termination provisions, assignment clauses and notice requirements. Ask your CVS contacts and 340B administrator how the separation could affect contracts, fees, reporting and operations. Remember that any lapse on contract pharmacy registrations/renewals due to this transition will still be the responsibility of the covered entity to maintain in the eyes of HRSA and the 340B OPAIS database so please ensure your records are up to date and correct at each step in this translation.
- Evaluate entity-owned pharmacy opportunities. Assess which prescriptions could be served through your own pharmacy, accounting for payer network access, operating costs and patient needs. Use that analysis to inform an investment decision.
A corporate restructuring changes ownership, which as a reminder in itself warrants OPAIS database changes. The resulting impact to patients will depend on what changes in access, choice and continuity of care transpire from the upcoming corporate split.
